Eyenovia Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Eyenovia kazanç ve gelirinin sırasıyla yıllık 37.7% ve 64% oranında artması tahmin edilirken, EPS'nin yıllık 44.8% oranında büyümesi bekleniyor.

Anahtar bilgiler

37.7%

Kazanç büyüme oranı

44.8%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	23.8%
Gelir büyüme oranı	64.0%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Low
Son güncelleme	18 Nov 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Kazanç ve Gelir Büyüme Tahminleri

NasdaqCM:EYEN - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	17	-26	-24	N/A	1
12/31/2025	5	-26	-30	N/A	3
12/31/2024	1	-37	-36	N/A	3
9/30/2024	0	-38	-31	-30	N/A
6/30/2024	0	-37	-32	-30	N/A
3/31/2024	0	-32	-30	-27	N/A
12/31/2023	0	-27	-28	-24	N/A
9/30/2023	0	-25	-27	-23	N/A
6/30/2023	N/A	-25	-26	-24	N/A
3/31/2023	N/A	-26	-25	-24	N/A
12/31/2022	N/A	-28	-26	-25	N/A
9/30/2022	10	-19	-27	-26	N/A
6/30/2022	10	-17	-25	-24	N/A
3/31/2022	12	-15	-26	-24	N/A
12/31/2021	14	-13	-22	-21	N/A
9/30/2021	6	-20	-11	-10	N/A
6/30/2021	6	-19	-7	-6	N/A
3/31/2021	4	-20	-6	-5	N/A
12/31/2020	2	-20	-7	-6	N/A
9/30/2020	N/A	-21	-16	-16	N/A
6/30/2020	N/A	-20	-18	-18	N/A
3/31/2020	N/A	-21	-19	-19	N/A
12/31/2019	N/A	-21	-19	-19	N/A
9/30/2019	N/A	-22	-19	-19	N/A
6/30/2019	N/A	-22	-19	-19	N/A
3/31/2019	N/A	-20	-17	-17	N/A
12/31/2018	N/A	-17	-13	-13	N/A
9/30/2018	N/A	-13	-11	-11	N/A
6/30/2018	N/A	-10	N/A	-8	N/A
3/31/2018	N/A	-7	N/A	-6	N/A
12/31/2017	N/A	-5	N/A	-5	N/A
9/30/2017	N/A	-4	N/A	-4	N/A
12/31/2016	N/A	-4	N/A	-3	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: EYEN önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: EYEN önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: EYEN önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: EYEN şirketinin gelirinin (yıllık 64% ) US pazarından (yıllık 9% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: EYEN şirketinin gelirinin (yıllık 64% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: EYEN 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Eyenovia Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Consensus revenue estimates decrease by 47%

Price target decreased by 11% to US$8.33

Consensus revenue estimates decrease by 32%, EPS upgraded

Consensus revenue estimates increase by 40%

Consensus revenue estimates increase by 27%

Consensus revenue estimates increase by 32%

Recent updates

New minor risk - Profitability

New major risk - Market cap size

Eyenovia, Inc. Provides Update on Phase 3 CHAPERONE Study

Eyenovia, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Eyenovia, Inc. Announces Presentation of Phase 3 Clobetasol Study Results at the American Academy of Ophthalmology (AAO) 2024 Expo

Eyenovia, Inc. has filed a Follow-on Equity Offering in the amount of $25 million.

Eyenovia, Inc. has filed a Follow-on Equity Offering in the amount of $4 million.

Eyenovia, Inc. Receives A Letter from the Staff of the Nasdaq Stock Market Regarding Bid Price Requirement

Eyenovia, Inc. Announces Chief Financial Officer Changes

Eyenovia, Inc. has completed a Follow-on Equity Offering in the amount of $5.14 million.

Eyenovia, Inc. has filed a Follow-on Equity Offering.

New major risk - Financial position

Consensus revenue estimates decrease by 47%

Price target decreased by 11% to US$8.33

Eyenovia, Inc. to Report Q2, 2024 Results on Aug 12, 2024

Eyenovia Receives Letter from Nasdaq Due to Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market Under Nasdaq Listing Rule 5550(a)(2)

New major risk - Shareholder dilution

Consensus revenue estimates decrease by 32%, EPS upgraded

Eyenovia, Inc. to Report Q1, 2024 Results on May 15, 2024

Eyenovia, Inc., Annual General Meeting, Jun 12, 2024

Eyenovia Provides Clinical and Scientific Update on FDA-Approved Products Mydcombi and Clobetasol Propionate Ophthalmic Suspension

New major risk - Share price stability

Eyenovia, Inc. has filed a Follow-on Equity Offering in the amount of $2 million.

Consensus revenue estimates increase by 40%

Consensus revenue estimates increase by 27%

Consensus revenue estimates increase by 32%

Eyenovia, Inc. to Report Q4, 2023 Results on Mar 18, 2024

Price target decreased by 8.6% to US$10.67

Consensus revenue estimates increase by 33%

Consensus revenue estimates increase by 33%

Is Eyenovia (NASDAQ:EYEN) Weighed On By Its Debt Load?

Consensus revenue estimates increase by 54%

New minor risk - Share price stability

High number of new directors

Eyenovia, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Eyenovia, Inc. Announces Fda Approval of Coastline International as Contract Manufacturer to Initiate Mydcombi Commercial Production

Is Eyenovia (NASDAQ:EYEN) Using Debt In A Risky Way?

Eyenovia, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Is Eyenovia (NASDAQ:EYEN) Using Debt Sensibly?

Insider recently bought US$234k worth of stock

Eyenovia, Inc., Annual General Meeting, Jun 27, 2023

Eyenovia, Inc. Announces FDA Approval of Mydcombi, the First Ophthalmic Spray for Mydriasis

Eyenovia, Inc. to Report Q1, 2023 Results on May 11, 2023

Co-Founder recently sold US$300k worth of stock

Co-Founder notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

No longer forecast to breakeven

No longer forecast to breakeven

Eyenovia, Inc. Showcases Microdose Array Print (MAP™) Technology At CES 2023 in Las Vegas

Eyenovia, Inc. Announces Positive Results from a Research Study

Forecast to breakeven in 2025

High number of new directors

Eyenovia Aims to Revolutionize Ophthalmology Devices with Microdose Array Print (Map) Technology

Eyenovia, Inc. Announces U.S. Food and Drug Administration Acceptance of New Drug Application for MydCombi™ for In-Office Pupil Dilation

Eyenovia, Inc. Announces Promotion of Bren Kern to Chief Operating Officer and Corporate Vice President, Effective January 1, 2023 and Julia Haller Steps Down from its Board of Directors

Price target decreased to US$14.33

Third quarter 2022 earnings released: US$0.21 loss per share (vs US$0.21 loss in 3Q 2021)

Third quarter 2022 earnings released: US$0.21 loss per share (vs US$0.21 loss in 3Q 2021)

Eyenovia, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Does Eyenovia (NASDAQ:EYEN) Have A Healthy Balance Sheet?

Eyenovia, Inc Announces Positive Results from VISION-2 Phase 3 Study of MicroLine as a Potential On-Demand Treatment for Presbyopia

Eyenovia gains as H.C. Wainwright initiates with Buy on pipeline potential

Eyenovia, Inc. Announces Retirement of Ken Lee as Lead Independent Director

Eyenovia's Novel Optejet® Dispenser Puts People's Eyes First

First half 2022 earnings released

Eyenovia, Inc. to Report Q2, 2022 Results on Aug 10, 2022

Eyenovia, Inc. Announces Board Changes

Eyenovia names Michael Rowe as new CEO